Unleashing the Power of Men's Health: Whittier Street Health Center to Shine Spotlight on Equity and Access

June 3, 2024 9:00 AM

Critical conversations about men's physical, mental, and emotional well-beingBOSTON, MA / ACCESSWIRE / June 3, 2024 / Whittier Street Health Center, a community health center dedicated to providing high-quality and accessible healthcare and social services to achieve health equity, social justice, and the economic well-being of a diverse patient population, is holding its Annual Men's Health Summit on Saturday, June 22, 2024. The event, themed...

Read more

MedTech Outlook 2024 for Latin America Released

June 3, 2024 9:00 AM

MIAMI, FL / ACCESSWIRE / June 3, 2024 / Global Health Intelligence (GHI), the leading healthcare data analytics provider in Latin America, has just published MedTech Outlook: Latin America 2024. MedTech Outlook: Latin America 2024 A comprehensive report on the medical equipment and device market in Latin America Exclusively created for medical equipment/device manufacturers operating in Latin America, this unique report features more than 1,500...

Read more

Candel Therapeutics (NASDAQ: CADL) Reports Positive Data From Phase 2 Trial Of CAN-2409 In Borderline Resectable Pancreatic Cancer

June 3, 2024 9:00 AM

Clinical-stage biopharmaceutical company Candel Therapeutics, Inc. (NASDAQ:CADL) reported updated survival data from its randomized phase 2 clinical trial of CAN-2409 in borderline resectable pancreatic cancer. Pancreatic cancer is the fourth leading cause of cancer-related death in the U.S. The disease accounts for approximately 3% of all cancers, with an estimated 64,050 patients diagnosed in 2023. The randomized, controlled clinical trial is...

Read more

Enzolytics, Inc. Poised to Invest Alongside Sagaliam Acquisition Corp in Revolutionary Room Temperature SPAD Technology

June 3, 2024 8:45 AM

ALLEN, TX / ACCESSWIRE / June 3, 2024 / Enzolytics, Inc. (OTC PINK:ENZC) ("enzolytics.com")(the "Company") is thrilled to announce that the Company and Sagaliam Acquisition Corp ("SAGA") are negotiating a landmark investment of six million US dollars ($6,000,000). This investment includes three million dollars in cash and an equivalent amount in a combination of the Company and SAGA common stock, in exchange for a non-dilutable thirty percent...

Read more

Monogram Technologies to Host Investor and Analyst Tour at its Headquarters in Austin, Texas, on Thursday, June 20th, 2024

June 3, 2024 8:31 AM

Monogram Technologies Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), an AI-driven robotics company focused on improving human health with an initial focus on orthopedic surgery, will host an investor and analyst day on Thursday, June 20th, 2024, from 9:00 a.m. CDT to 1:00 p.m. CDT at its cadaver lab and headquarters in Austin, Texas.Monogram Chief Executive Officer Ben Sexson, Founder & Chief Medical Officer Dr. Douglas Unis, Chief Technology...

Read more

Sector Spotlight: Orphan Drug Developers With Significant Upside

June 3, 2024 8:15 AM

The biotech sector is finally beginning to recover following a two year stretch of underperformance that was largely driven by rising interest rates and other macro factors. Biotech has a track record of strong recoveries, with the sector typically seeing double-digit gains after a downturn. This is something investors shouldn't ignore.This recent turnaround can be credited to a robust increase in fundraising efforts and an uptick in IPOs,...

Read more

CNS Pharmaceuticals Announces Reverse Stock Split

June 3, 2024 8:05 AM

CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced a 1-for-50 reverse split of its common stock, effective at 4:01 PM ET on June 4, 2024. Beginning on June 5, 2024, the Company's common stock will continue to trade on The Nasdaq Capital Market ("Nasdaq") on a...

Read more

Aptevo Participating in the BIO International Convention

June 3, 2024 8:05 AM

Aptevo Therapeutics Inc. (Nasdaq:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today announced that the Company is participating in the BIO International Convention occurring June 3-6, 2024 in San Diego, CA.The conference is known for being the largest biotechnology industry conference of the year and is expected to...

Read more

Moderna & Merck Announce 3-Year Data For mRNA-4157 (V940) in Combination With KEYTRUDA(R) (pembrolizumab) Demonstrated Sustained Improvement in Recurrence-Free Survival & Distant Metastasis-Free Survival Versus KEYTRUDA in Patients With High-Risk Stage III/IV Melanoma Following Complete Resection

June 3, 2024 8:00 AM

CAMBRIDGE, MA and RAHWAY, NJ / ACCESSWIRE / June 3, 2024 / Moderna, Inc. (NASDAQ:MRNA) and Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced the first presentation of results from a planned analysis from the Phase 2b randomized KEYNOTE-942/mRNA-4157-P201 study, a clinical trial evaluating mRNA-4157 (V940), an investigational individualized neoantigen therapy (INT), in combination with KEYTRUDA, Merck's...

Read more

Modular Medical Announces Addition to the Russell Microcap(R) Index

June 3, 2024 8:00 AM

Modular Medical, Inc. (NASDAQ:MODD) ("Modular Medical"), a development-stage, insulin delivery technology company seeking to launch the next generation of user-friendly and affordable insulin pump technology, today announced that it is set to join the Russell Microcap Index at the conclusion of the 2024 Russell indexes annual reconstitution, effective when the U.S. market opens on July 1, 2024.Membership in the Russell Microcap Index, which...

Read more

Nutriband Inc. Quarterly Report Emphasizes Focus on Kinesiology Tape Output as Q1 Sports Tape Revenues Increase 219% Year Over Year

June 3, 2024 7:00 AM

ORLANDO, FL / ACCESSWIRE / June 3, 2024 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), today reported Q1 revenues of $408,532 emphasizing its focus on expanding the company's Kinesiology Tape manufacturing services through its Pocono Pharma subsidiary. The Company has been focused on using penetration pricing to gain a foothold with some of the industry's largest brands and License holders such as KT Tape and Fit For Life Group, who hold licenses...

Read more

Amphastar Pharmaceuticals to Present at the Jefferies Global Healthcare Conference

June 3, 2024 6:00 AM

RANCHO CUCAMONGA, CA / ACCESSWIRE / June 3, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO, and Jacob Liawatidewi, EVP of Corporate Administration, will participate in an Analyst-Moderated fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 6, 2024 at 12:30 pm EST. For access, visit Amphastar's Pharmaceuticals website at http://ir.amphastar.com. This webcast will be available...

Read more

Hemogenyx Pharmaceuticals PLC Announces Posting of Annual Report & Notice of AGM

June 3, 2024 2:00 AM

Hemogenyx Pharmaceuticals plc (LSE:HEMO), the biopharmaceutical group, confirms that the Annual Report and Accounts for the year ended 31 December 2023, the Notice of the Annual General Meeting ("AGM") and a Form of Proxy will be posted to shareholders today and are available on the Company's website at https://hemogenyx.com/investors/annual-half-year-reports/.The AGM is to be held on 27 June 2024 at 2.00 pm BST at the offices of SP Angel...

Read more

Genflow Biosciences PLC Announces Notice of AGM

June 3, 2024 2:00 AM

Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow" or "the Company") an emerging leader in the field of longevity research, focused on developing therapeutic solutions for the prevention of age-related diseases is pleased to announce that it will hold its Annual General Meeting ("AGM") at 12pm on Thursday 27 June 2024 at 1 Heddon Street, London, W1B 4BT.The Notice of the AGM ("Notice") and 2024 Form of Proxy will shortly be available on...

Read more

Relief Therapeutics Announces Executive Changes

June 3, 2024 1:20 AM

RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (Relief Therapeutics, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, today announced that interim Chief Executive Officer Michelle Lock has completed her transitional mandate with the Company. Her contract was not renewed upon its expiration on May 31, 2024. Ms. Lock will also not...

Read more

Cantargia ASCO Presentation Highlights Positive Clinical Data on Nadunolimab Counteracting Neuropathy

June 1, 2024 2:40 PM

LUND, SWEDEN / ACCESSWIRE / June 1, 2024 / Cantargia (STO:CANTA) Cantargia (Cantargia AB; Nasdaq Stockholm: CANTA) today gave a presentation at the ASCO conference showing clinical data on nadunolimab counteracting the serious problem of chemotherapy induced neuropathy, an additional positive finding beyond its promising antitumor effects. The data focus on 73 pancreatic cancer patients receiving nadunolimab and chemotherapy. A key finding is...

Read more

KindlyMD Announces Pricing of $6.8 Million Initial Public Offering

May 31, 2024 11:45 AM

SALT LAKE CITY, UT / ACCESSWIRE / May 31, 2024 / KindlyMD, Inc. (NASDAQ:KDLY)(NASDAQ:KDLYW) ("KindlyMD" or the "Company"), a patient-first healthcare and healthcare data company uniquely integrating traditional primary care and pain management strategies with integrated behavioral and alternative therapies, including the recommendation of medical cannabis in patient treatment plans in compliance with a legalized state medical cannabis regulatory...

Read more

Moderna Receives U.S. FDA Approval for RSV Vaccine mRESVIA(R)

May 31, 2024 10:58 AM

CAMBRIDGE, MA / ACCESSWIRE / May 31, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced that the U.S. Food and Drug Administration (FDA) has approved mRESVIA (mRNA-1345), an mRNA respiratory syncytial virus (RSV) vaccine, to protect adults aged 60 years and older from lower respiratory tract disease caused by RSV infection. The approval was granted under a breakthrough therapy designation and marks the second approved mRNA product from...

Read more

Cloud DX Reports Results for the First Quarter of 2024

May 31, 2024 10:45 AM

Highlights include 23.7% increase in subscription revenue, 23.7% increase in total revenue, and 70.9% increase in gross profit compared to the first quarter of 2023.Key Developments in 2024:Cloud DX has now announced 26 new contracts and/or contract renewals so far in 2024. Notable announcements include new contracts with Ontario Paramedics, Ottawa University Research Institute, VHA Home HealthCare and Health PEI. Together the announced value of...

Read more

Sound Physicians Closes Liquidity Enhancing Transaction

May 31, 2024 8:50 AM

Strengthening its financial position with an infusion of new capital that will bolster its operations and practices, coast to coastNEW YORK, NY / ACCESSWIRE / May 31, 2024 / Sound Physicians, a leading provider of hospital-based physician services and value-based care within the post-acute setting, today announced it has successfully consummated the liquidity enhancing, holistic transaction previously announced on May 21. Read the full release...

Read more